| 刘晓红,刘俐惠,杨慕坤,等.血清 AMH、TRACP5b联合检测对更年期女性发生骨质疏松症的预测价值[J].安徽医药,2025,29(9):1796-1805. |
| 血清 AMH、TRACP5b联合检测对更年期女性发生骨质疏松症的预测价值 |
| Study on the predictive value of combined detection of serum AMH and TRACP5b expression levels for occurrence of osteoporosis in menopausal women |
| |
| DOI：10.3969/j.issn.1009-6469.2025.09.020 |
| 中文关键词: 骨质疏松 更年期 抗米勒管激素 抗酒石酸酸性磷酸酶 5b 预测价值研究 骨质疏松症 |
| 英文关键词: Osteoporosis Climacteric Anti Mullerian hormone Tartrate resistant acid phosphatase 5b Research on predictive value Osteoporosis |
| 基金项目:首都医科大学附属北京世纪坛医院科研课题( 2018-q36)；中国国家铁路集团有限公司科技研究开发计划项目( J2021Z607) |
|
| 摘要点击次数: 238 |
| 全文下载次数: 513 |
| 中文摘要: |
| 目的探讨血清抗米勒管激素( AMH)、抗酒石酸酸性磷酸酶 5b(TRACP5b)水平联合检测对更年期女性发生骨质疏松症的预测价值。方法选取 2020年 5月至 2022年 5月在首都医科大学附属北京世纪坛医院诊治的更年期女性 163例为研究对象，将其分为骨质疏松组( n=60)、骨量减少组( n=49)、骨量正常组( n=54)。运用全自动免疫分析仪和酶联免疫吸附分析(ELISA)分别检测血清 AMH、TRACP5b表达水平；采用 Pearson法分析骨质疏松病人血清 AMH、TRACP5b水平的相关性；血清 AMH、TRACP5水平对更年期女性发生骨质疏松症的预测价值运用受试者操作特征曲线( ROC曲线)进行评估。结果骨量正常组、骨量减少组、骨质疏松组更年期女性骨密度( BMD)比较，差异有统计学意义［(1.17±0.34)g/cm2(0.96±0.21)g/cm2、(0.78±0.19)g/cm2，P<0.05］；骨质疏松组血清 AMH表达水平低于骨量正常组、/L比( 1.06±0.33)μg/L、骨量减少组［(0.28±0.08)μg、(0.78±0.24)μg/L］血清 TRACP5b水平高于骨量减少组、骨量正常组［( 4.85±1.36)U/L比( 4.33±1.21)U/L、(3.35±1.01)U/L］(P<0.05)；骨质疏松血清 AMH、TRACP5b水平呈负相关性( r=.0.42，P<0.05)；血清 AMH、TRACP5b预测更年期女性发生骨质疏松症的曲线下面积(AUC)分别为 0.82、0.86，二者联合检测预测更年期女性发生骨质疏松症的 AUC(0.94)高于各指标单独检测( Z二者联合 -AMH=2.36，Z二者联合 -TRACP5b=2.52，P=0.018、0.012)。结论血清 AMH、TRACP5b二者联合检测可较好地预测更年期女性病人， |
| 英文摘要: |
| Objective To explore the predictive value of combined detection of serum levels of anti Mullerian hormone (AMH) andtartrate resistant acid phosphatase 5b (TRACP5b) for occurrence of osteoporosis in menopausal women.Methods A total of 163 meno-pausal women who were diagnosed and treated in Beijing Shijitan Hospital from May 2020 to May 2022 were selected as the study sub-jects. They were grouped into an osteoporosis group (n=60), a bone loss group (n=49), and a normal bone mass group (n=54). Rocheelectrochemical luminescence immunoassay analyzer was applied to detect serum AMH expression level, enzyme linked immunosor-bent assay (ELISA) was applied to measure the expression level of serum TRACP5b; Pearson method was applied to analyze the correla-tion between serum AMH and TRACP5b levels in patients with osteoporosis; receiver operating characteristic curve(ROC curve) wasapplied to evaluate the predictive value of serum AMH and TRACP5 levels for the occurrence of osteoporosis in menopausal women.Re. sults There was a obvious difference in bone mineral density (BMD) among the osteoporosis group, osteopenia group, and normalbone mass group [(1.17±0.34) g/cm2, (0.96±0.21) g/cm2, (0.78±0.19) g/cm2, P<0.05]; the serum AMH level in the osteoporosis groupwas lower than that in the normal bone mass group and the osteopenia group [(0.28±0.08) μg/L vs. (1.06±0.33) μg/L, (0.78±0.24) μg/L],while the serum TRACP5b level was higher than that in the osteopenia group and normal bone mass group [(4.85±1.36) U/L vs. (4.33± 1.21) U/L, (3.35±1.01) U/L] (P<0.05); the serum levels of AMH and TRACP5b in patients with osteoporosis showed a negative correla-tion (r=.0.42, P<0.05); the area under the curve (AUC) of serum AMH and TRACP5b in predicting the occurrence of osteoporosis inmenopausal women was 0.82 and 0.86, the AUC (0.94) of the combined test for predicting osteoporosis in menopausal women was high-er than that of the single test for each index (Zcombined-AMH=2.36, Zcombined-TRACP5b=2.52, P=0.018, 0.012).Conclusion The combined detec-tion of serum AMH and TRACP5b can effectively predict the occurrence of osteoporosis in menopausal women, providing theoretical di-rection for clinical treatment of osteoporosis in menopausal women. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
